Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; LX9211, which is in Phase II clinical development for the treatment of neuropathic pain; and LX2761. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in The Woodlands, Texas.
IPO Year:
Exchange: NASDAQ
Website: lexpharma.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/5/2025 | $2.00 → $1.00 | Outperform → Market Perform | Leerink Partners |
| 6/17/2024 | $10.00 | Buy | H.C. Wainwright |
| 4/30/2024 | $5.00 | Outperform | Leerink Partners |
| 3/7/2023 | $3.00 | Hold | Jefferies |
| 8/12/2022 | $10.00 | Overweight | Piper Sandler |
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - LEXICON PHARMACEUTICALS, INC. (0001062822) (Issuer)
4 - LEXICON PHARMACEUTICALS, INC. (0001062822) (Issuer)
4 - LEXICON PHARMACEUTICALS, INC. (0001062822) (Issuer)
4 - LEXICON PHARMACEUTICALS, INC. (0001062822) (Issuer)
4 - LEXICON PHARMACEUTICALS, INC. (0001062822) (Issuer)
4 - LEXICON PHARMACEUTICALS, INC. (0001062822) (Issuer)
4 - LEXICON PHARMACEUTICALS, INC. (0001062822) (Issuer)
4 - LEXICON PHARMACEUTICALS, INC. (0001062822) (Issuer)
4 - LEXICON PHARMACEUTICALS, INC. (0001062822) (Issuer)
4 - LEXICON PHARMACEUTICALS, INC. (0001062822) (Issuer)
Fastest customizable press release news feed in the world
THE WOODLANDS, Texas, June 03, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) today announced that it will present data from clinical studies of sotagliflozin in Type 1 diabetes (T1D) and pilavapadin in diabetic peripheral neuropathic pain (DPNP) at the American Diabetes Association (ADA) 2026 Scientific Sessions, being held June 5-8 in New Orleans, Louisiana. "We look forward to engaging with the diabetes community at ADA 2026, as well as sharing additional data from clinical studies of our novel, orally administered investigational therapies for T1D and DPNP," said Craig Granowitz, M.D., Ph.D., Lexicon's senior vice president and chief medical officer. "In particul
THE WOODLANDS, Texas, May 28, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) today announced that Company management will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference on June 4, 2026 at 2:00 p.m. ET in New York City. The live event and a replay of the presentation can be accessed via the Events page of the Company's website at https://investors.lexpharma.com/. About Lexicon Pharmaceuticals Lexicon is a biopharmaceutical company with a mission of pioneering medicines that transform patients' lives. Lexicon has a pipeline of drug candidates in discovery, preclinical, and clinical development in neuropathic pain, hypertrophic car
THE WOODLANDS, Texas, May 12, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) today announced that Company management will participate in a fireside chat at the 4th Annual H.C. Wainwright BioConnect Investor Conference, taking place at the Nasdaq World Headquarters in New York City, on May 19, 2026. The live event and a replay of the presentation can be accessed via the Events page of the Company's website at https://investors.lexpharma.com/. About Lexicon Pharmaceuticals Lexicon is a biopharmaceutical company with a mission of pioneering medicines that transform patients' lives. Lexicon has a pipeline of drug candidates in discovery, preclinical, and clinical deve
SONATA-HCM anticipated to be fully enrolled mid-2026 Resubmission of NDA for ZYNQUISTA® in type 1 diabetes anticipated mid-2026 with potential for approval this year Clinical development of LX9851 initiated by Novo Nordisk Capital raise, development milestone payments, and recent $100 million loan facility reinforce strong financial position Conference call and webcast at 8:30 am ET THE WOODLANDS, Texas, May 07, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX), today reported financial results for the three months ended March 31, 2026, and provided an update on key corporate milestones and accomplishments. "We have been intently focused on progressing our la
THE WOODLANDS, Texas, May 04, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) announced today that it has entered into a loan facility with Hercules Capital, Inc. (NYSE:HTGC) that provides up to $100 million in borrowing capacity. Access to this non-dilutive capital provides Lexicon with greater financial flexibility through both an extended interest-only period and maturity date and the opportunity to further strengthen its balance sheet to support pivotal upcoming regulatory and commercial milestones. "Operational excellence, financial discipline and financial flexibility are key pillars of our corporate strategy for long-term growth," said Scott Coiante, Lexicon's
THE WOODLANDS, Texas, April 30, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) today announced the Company will release its first quarter 2026 financial results on Thursday, May 7, 2026, prior to market open. Management will conduct a conference call and live webcast at 8:30 a.m. ET (7:30 a.m. CT) that day to discuss the financial results and to provide a business update. Participants can access the conference call live via webcast on the Events page of the Company's website at https://investors.lexpharma.com/. Participants who wish to ask a question may join by phone at 800-715-9871 and use passcode 9826247. An archived version of the webcast will be available on t
Oral presentation highlights additional data from PROGRESS Phase 2b study of pilavapadin supporting selection of 10mg as optimal dose for Phase 3 development in DPNP New data on spasticity further validates the broader potential importance of the AAK1 pathway in neurologic diseases THE WOODLANDS, Texas, April 17, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) today announced that results from its PROGRESS Phase 2b study of pilavapadin in diabetic peripheral neuropathic pain (DPNP) supporting the selection of pilavapadin 10 mg as the optimal dose for Phase 3 development will be presented on Wednesday April 22, during the American Academy of Neurology (AAN) Annual
THE WOODLANDS, Texas, March 24, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) today announced three presentations of sotagliflozin clinical data during the American College of Cardiology (ACC) Annual Meeting. The congress is being held March 28-30 in New Orleans, Louisiana. Lexicon will present data from the Phase 3 SCORED study of sotagliflozin in people with type 2 diabetes, chronic kidney disease and other cardiovascular risk factors. In a prespecified analysis, patients were stratified by baseline body mass index (BMI), and the results demonstrated that sotagliflozin reduced heart failure and major adverse cardiovascular events (MACE) irrespective of BMI. Prese
THE WOODLANDS, Texas, March 11, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) today announced that results of a post hoc analysis of clinical data evaluating the impact of kidney function on the long-term efficacy and safety of sotagliflozin on people with type 1 diabetes will be delivered as a short oral presentation tomorrow, March 12, during the 19th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD). The congress is being held March 11-14, 2026, in Barcelona, Spain. "Recognizing that a patient's kidney function can impact the efficacy of SGLT inhibitors, we conducted this post hoc analysis of clinical data from two identically-des
Pivotal sotagliflozin milestones on schedule including resubmission of NDA in T1D and enrollment of SONATA study for HCM Positive End-of-Phase 2 meeting with FDA for pilavapadin confirms Phase 3 readiness and supports ongoing partnership discussions Strengthened financial position with more than $100 million in additional cash from capital raise and Novo Nordisk milestone payment Conference call and webcast at 8:30 am ET THE WOODLANDS, Texas, March 05, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX), today reported financial results for the three months and year ended December 31, 2025, and provided an update on key corporate milestones and accomplishments. "
10-Q - LEXICON PHARMACEUTICALS, INC. (0001062822) (Filer)
8-K - LEXICON PHARMACEUTICALS, INC. (0001062822) (Filer)
8-K - LEXICON PHARMACEUTICALS, INC. (0001062822) (Filer)
8-K - LEXICON PHARMACEUTICALS, INC. (0001062822) (Filer)
DEFA14A - LEXICON PHARMACEUTICALS, INC. (0001062822) (Filer)
DEF 14A - LEXICON PHARMACEUTICALS, INC. (0001062822) (Filer)
10-K - LEXICON PHARMACEUTICALS, INC. (0001062822) (Filer)
8-K - LEXICON PHARMACEUTICALS, INC. (0001062822) (Filer)
PRE 14A - LEXICON PHARMACEUTICALS, INC. (0001062822) (Filer)
D - LEXICON PHARMACEUTICALS, INC. (0001062822) (Filer)
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
Live FDA approvals issued by the Food and Drug Administration and FDA breaking news
Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.
Leerink Partners downgraded Lexicon Pharma from Outperform to Market Perform and set a new price target of $1.00 from $2.00 previously
H.C. Wainwright initiated coverage of Lexicon Pharma with a rating of Buy and set a new price target of $10.00
Leerink Partners initiated coverage of Lexicon Pharma with a rating of Outperform and set a new price target of $5.00
Jefferies initiated coverage of Lexicon Pharma with a rating of Hold and set a new price target of $3.00
Piper Sandler initiated coverage of Lexicon Pharma with a rating of Overweight and set a new price target of $10.00
Wedbush downgraded Lexicon Pharma from Outperform to Neutral and set a new price target of $8.00 from $2.00 previously
JP Morgan upgraded Lexicon Pharma from Underweight to Neutral and set a new price target of $7.00
Submission status for LEXICON PHARMACEUTICALS INC's drug INPEFA (ORIG-1) with active ingredient SOTAGLIFLOZIN has changed to 'Approval' on 05/26/2023. Application Category: NDA, Application Number: 216203, Application Classification: Type 1 - New Molecular Entity
4 - LEXICON PHARMACEUTICALS, INC. (0001062822) (Issuer)
4 - LEXICON PHARMACEUTICALS, INC. (0001062822) (Issuer)
4 - LEXICON PHARMACEUTICALS, INC. (0001062822) (Issuer)
4 - LEXICON PHARMACEUTICALS, INC. (0001062822) (Issuer)
4 - LEXICON PHARMACEUTICALS, INC. (0001062822) (Issuer)
4 - LEXICON PHARMACEUTICALS, INC. (0001062822) (Issuer)
4 - LEXICON PHARMACEUTICALS, INC. (0001062822) (Issuer)
4 - LEXICON PHARMACEUTICALS, INC. (0001062822) (Issuer)
Live Leadership Updates
THE WOODLANDS, Texas, Jan. 02, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) today announced the appointment of Scott Coiante as senior vice president and chief financial officer, effective today, January 2, 2025. Mr. Coiante is a senior finance executive with more than 35 years of experience in the life science and pharmaceutical industries. He joins Lexicon from Agile Therapeutics, where he served as the senior vice president, chief financial officer and treasurer of Agile Therapeutics Inc. from August 2023 to August 2024, as well as from 2011-2019. "I am pleased to join Lexicon at this pivotal moment for the company and eager to contribute to its
THE WOODLANDS, Texas, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) today announced that Ivan H. Cheung has been elected to its Board of Directors. Mr. Cheung is a biopharmaceutical executive with more than 25 years of experience in the healthcare industry and a proven track record of shareholder value creation. He is currently the chief executive officer and a director of NextPoint Therapeutics, and he has served as senior advisor to TPG Growth – a growth investing platform within global asset manager TPG – since September 2023. "I am honored to join the Lexicon Board of Directors at this pivotal moment in the company's history, and to support its mis
THE WOODLANDS, Texas, July 08, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) today announced that the Lexicon Board of Directors has appointed Mike Exton, Ph.D. as chief executive officer and director of Lexicon. Dr. Exton succeeds Lonnel Coats who, as previously announced, retired effective July 7, 2024. Dr. Exton most recently served as the global cardiometabolic therapeutic head at Novartis. "I am confident that Mike is the right person to serve as Lexicon's next chief executive officer at this critical time for the company," said Ray Debbane, chairman of Lexicon's board of directors. "He is an inspiring leader with a demonstrated track record of success, includi
Live finance-specific insights
SONATA-HCM anticipated to be fully enrolled mid-2026 Resubmission of NDA for ZYNQUISTA® in type 1 diabetes anticipated mid-2026 with potential for approval this year Clinical development of LX9851 initiated by Novo Nordisk Capital raise, development milestone payments, and recent $100 million loan facility reinforce strong financial position Conference call and webcast at 8:30 am ET THE WOODLANDS, Texas, May 07, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX), today reported financial results for the three months ended March 31, 2026, and provided an update on key corporate milestones and accomplishments. "We have been intently focused on progressing our la
THE WOODLANDS, Texas, April 30, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) today announced the Company will release its first quarter 2026 financial results on Thursday, May 7, 2026, prior to market open. Management will conduct a conference call and live webcast at 8:30 a.m. ET (7:30 a.m. CT) that day to discuss the financial results and to provide a business update. Participants can access the conference call live via webcast on the Events page of the Company's website at https://investors.lexpharma.com/. Participants who wish to ask a question may join by phone at 800-715-9871 and use passcode 9826247. An archived version of the webcast will be available on t
Pivotal sotagliflozin milestones on schedule including resubmission of NDA in T1D and enrollment of SONATA study for HCM Positive End-of-Phase 2 meeting with FDA for pilavapadin confirms Phase 3 readiness and supports ongoing partnership discussions Strengthened financial position with more than $100 million in additional cash from capital raise and Novo Nordisk milestone payment Conference call and webcast at 8:30 am ET THE WOODLANDS, Texas, March 05, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX), today reported financial results for the three months and year ended December 31, 2025, and provided an update on key corporate milestones and accomplishments. "
THE WOODLANDS, Texas, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) today announced the Company will release its fourth quarter 2025 financial results on Thursday, March 5, 2026, prior to market open. Management will conduct a conference call and live webcast at 8:30 a.m. ET (7:30 a.m. CT) that day to discuss the financial results and to provide a business update. Participants can access the conference call live via webcast on the Events page of the Company's website at https://investors.lexpharma.com/. Participants who wish to ask a question may register here to receive dial-in numbers and a unique pin to join the call. An archived version of the webcast w
FDA End-of-Phase 2 meeting for pilavapadin in DPNP to be held by year-end All IND-enabling studies of LX9851 for obesity completed and submitted to licensee Novo Nordisk Site initiation for SONATA-HCM Phase 3 study of sotagliflozin in both obstructive and non-obstructive HCM completed; enrollment completion on target for 2026 Additional data in support of potential resubmission of Zynquista for type 1 diabetes submitted to FDA Conference call and webcast at 8:30 am ET THE WOODLANDS, Texas, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX), today reported financial results for the three months ended September 30, 2025, and provided an update on key corpo
THE WOODLANDS, Texas, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) today announced the Company will release its third quarter 2025 financial results on Thursday, November 6, 2025, prior to market open. Management will conduct a conference call and live webcast at 8:30 a.m. ET (7:30 a.m. CT) that day to discuss the financial results and to provide a business update. Participants can access the conference call live via webcast on the Events page of the Company's website at https://investors.lexpharma.com/. Participants who wish to ask a question may register here to receive dial-in numbers and a unique pin to join the call. An archived version of the webcast
Partnership discussions for pilavapadin remain underway following Phase 2b PROGRESS study results IND-enabling studies of LX9851 for obesity and related disorders on track for completion in 2025 with licensee Novo Nordisk expected to submit IND Enrollment completion for SONATA Phase 3 study in both obstructive and non-obstructive hypertrophic cardiomyopathy (HCM) on target for 2026 Conference call and webcast at 8:30 am ET THE WOODLANDS, Texas, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX), today reported financial results for the three months ended June 30, 2025, and provided an update on key corporate milestones and accomplishments. "We continue t
THE WOODLANDS, Texas, July 23, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) today announced the Company will release its second quarter 2025 financial results on Wednesday, August 6, 2025, prior to market open. Management will conduct a conference call and live webcast at 8:30 a.m. ET (7:30 a.m. CT) that day to discuss the financial results and to provide a business update. Participants can access the conference call live via webcast on the Events page of the Company's website at https://investors.lexpharma.com/. Participants who wish to ask a question may register here to receive dial-in numbers and a unique pin to join the call. An archived version of the webcast
Company had a strong start to 2025, emerging as an R&D-focused organization Exclusive license agreement with Novo Nordisk for LX9851 executed; IND-enabling studies on track for completion in 2025 Phase 2b PROGRESS study confirmed 10 mg pilavapadin as appropriate dose for advancement into Phase 3 development for diabetic peripheral neuropathic pain Conference call and webcast at 5:00 pm ET THE WOODLANDS, Texas, May 13, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX), today reported financial results for the three months ended March 31, 2025, and provided an update on key corporate milestones and accomplishments. "We began 2025 delivering on three of our goals for
THE WOODLANDS, Texas, May 06, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) today announced the Company will release its first quarter 2025 financial results on Tuesday, May 13, 2025, after the markets close. Management will conduct a conference call and live webcast at 5:00 p.m. ET (4:00 p.m. CT) that day to discuss the financial results and to provide a business update. Participants can access the conference call live via webcast on the Events page of the Company's website at https://investors.lexpharma.com/. Participants who wish to ask a question may register here to receive dial-in numbers and a unique pin to join the call. An archived version of the webcast wi
This live feed shows all institutional transactions in real time.
SC 13D/A - LEXICON PHARMACEUTICALS, INC. (0001062822) (Subject)
SC 13G/A - LEXICON PHARMACEUTICALS, INC. (0001062822) (Subject)
SC 13G/A - LEXICON PHARMACEUTICALS, INC. (0001062822) (Subject)
SC 13D/A - LEXICON PHARMACEUTICALS, INC. (0001062822) (Subject)
SC 13G - LEXICON PHARMACEUTICALS, INC. (0001062822) (Subject)
SC 13D/A - LEXICON PHARMACEUTICALS, INC. (0001062822) (Subject)
SC 13D/A - LEXICON PHARMACEUTICALS, INC. (0001062822) (Subject)
SC 13G/A - LEXICON PHARMACEUTICALS, INC. (0001062822) (Subject)
SC 13D/A - LEXICON PHARMACEUTICALS, INC. (0001062822) (Subject)
SC 13G/A - LEXICON PHARMACEUTICALS, INC. (0001062822) (Subject)